Skip to main content

Table 2 Multivariate analyses of association between clinical factors and anxiety in patients with rheumatoid arthritis (N = 508)

From: Factors associated with anxiety and depression in rheumatoid arthritis patients: a cross-sectional study

 

Univariable analysis

Multivariable analysis

Odds ratio (95% CI)

p value

Model 1

Model 2

Odds ratio (95% CI)

p value

Odds ratio (95% CI)

p value

Sex

0.99 (0.55, 1.89)

0.98

0.88 (0.45, 1.71)

0.71

0.83 (0.43, 1.63)

0.59

Age (10 years)

1.01 (0.84, 1.29)

0.98

0.83 (0.68, 1.01)

0.07

0.83 (0.68, 1.01)

0.06

DAS28-CRP non-remission

1.99 (1.12, 3.36)

0.01

0.93 (0.48, 1.78)

0.82

  

TJC

1.18 (1.03, 1.35)

0.02

  

1.02 (0.85, 1.22)

0.85

SJC

1.14 (0.98, 1.34)

0.08

  

0.97 (0.79, 1.19)

0.76

CRP

1.23 (0.90, 1.65)

0.17

  

1.01 (0.70, 1.43)

0.98

PtGA (0–10)

1.29 (1.18, 1.42)

 < 0.01

  

1.15 (1.02, 1.29)

0.03

HAQ-DI non-remission

4.32 (2.59, 7.48)

 < 0.01

3.51 (1.85, 6.64)

 < 0.01

3.21 (1.69, 6.08)

 < 0.01

Pain VAS (0–10)

1.24 (1.14, 1.35)

 < 0.01

1.10 (0.98, 1.23)

0.12

  

Biological DMARD

1.12 (0.69, 1.77)

0.65

1.07 (0.63, 1.80)

0.81

1.05 (0.62, 1.77)

0.85

Methotrexate

0.64 (0.40, 1.03)

0.06

0.67 (0.40, 1.13)

0.13

0.71 (0.42, 1.20)

0.20

Steroid

1.63 (1.01, 2.60)

0.04

1.12 (0.66, 1.92)

0.67

1.14 (0.66, 1.96)

0.64

  1. Model adjusted for age (stratified in 10 decades), pain (VAS), HAQ-DI remission, and treatment type
  2. VAS range: 0 (no pain) to 10 (maximum). Anxiety was measured using the HADS (HADS-A score ≥ 8). DAS28 was used for clinical remission (DAS28 score of < 2.6). DAS4 variables comprise TJC, SJC, CRP, and PtGA
  3. CI confidence interval, DAS28 Disease Activity Score in 28 joints, TJC tender joint count, SJC swollen joint count, PtGA patient global assessment, VAS Visual Analogue Scale, CRP C-reactive protein, HAQ-DI Health Assessment Questionnaire Disability Index, HADS Hospital Anxiety and Depression Scale, DMARD disease-modifying anti-rheumatic drug
Back to article page

Advances in Rheumatology

ISSN: 2523-3106